Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 13Nivolumab 6Cyclophosphamide 6Carboplatin 6Specimen Handling 5Pemetrexed 5Paclitaxel 5Docetaxel 5Cisplatin 5Cetuximab 5Bevacizumab 5fludarabine phosphate 4fludarabine 4atezolizumab 4tislelizumab 3durvalumab 3Standard of Care 3Practice Guidelines as Topic 3Methods 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Gemcitabine 3Educational Status 3Early Intervention, Educational 3130-nm albumin-bound paclitaxel 3venetoclax 2tremelimumab 2temsirolimus 2niraparib 2ixazomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Toll-Like Receptor 1 × 30 days × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡